Latest Investment News

EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.

City Chic Collective has reversed its fortunes with a $15 million EBITDA turnaround in FY25, driven by strategic restructuring and strong ANZ growth. The company eyes a debt-free 2025 close and cash flow positivity in FY26 amid cautious optimism for US market expansion.

Shaver Shop Group Limited reported a record gross margin of 45.5% and EBIT growth of 2.4% in FY25, alongside a strong fully franked dividend. The 2025 AGM saw shareholder approval of key governance items including executive incentives.

Shaver Shop Group Limited reported steady sales of $219 million for FY25, with a notable 2.1% rise in gross profit driven by its private brand Transform-U. The company’s strategic focus on exclusive products and store network optimization sets a positive tone for 2026.

Delta Lithium has updated its Mt Ida Mineral Resource Estimate to include a high-grade rubidium oxide resource, enhancing the project's critical mineral credentials and economic potential.

The Australian Competition and Consumer Commission has given the green light to Southern Cross Media’s proposed acquisition of Seven West Media, marking a significant regulatory milestone in the evolving Australian media landscape.

Superloop Limited has reported a robust FY25 performance with significant revenue and profitability gains, marking its entry into the ASX 200 index and advancing key ESG initiatives.

SGH Ltd reported record earnings and reaffirmed its FY26 EBIT growth guidance at its 2025 AGM, while addressing recent workplace fatalities and outlining strategic growth initiatives.

Antilles Gold has launched a substantial infill drilling program at its La Demajagua mine in Cuba, setting the stage for a Definitive Feasibility Study that could unlock enhanced resource value amid soaring gold, silver, and antimony prices.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.

Lycopodium Limited projects steady growth for FY26 with revenue guidance of $390-$410 million, underpinned by strong project momentum and the strategic SAXUM acquisition expanding its footprint in the Americas.